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Abstract Cancer is one of the leading causes of death in
most parts of the world and is a very serious cause of
concern particularly in developing countries. In this work,
we prepared and evaluated the aptamer-labeled paclitaxel-
loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles
(Apt-PTX-PLGA NPs) which can ameliorate drug bioavail-
ability and enable accurate drug targeting to cancer cells
with controlled drug release for cancer therapy. Paclitaxel-
loaded PLGA nanoparticles (PTX-PLGA NPs) were formu-
lated by a single-emulsion/solvent evaporation method and
were further surface-functionalized with a chemical cross-
linker bis(sulfosuccinimidyl) suberate (BS3) to enable binding
of aptamer on to the surface of the nanoparticles. The prepared
nanoparticles were characterized by atomic force microscopy,
scanning electron microscopy, and X-ray photoelectron spec-
troscopy. Cytotoxicity studies were carried out using normal
human mammary epithelial cells (HMEC cells) and human
glial cancer cells (GI-1 cells) by methylthiazolyldiphenyl-
tetrazolium bromide assay and Alamar blue assay, which con-
firmed that PTX-PLGA NPs with aptamer conjugation (Apt-
PTX-PLGA NPs) were comparatively non-toxic to HMEC
cells while toxic to GI-1 cancer cells. Cellular uptake of
PTX-PLGA NPs with and without aptamer conjugation was
studied using GI-1 cells and monitored by confocal microsco-
py and phase contrast microscopy. Our studies demonstrated
significant internalization and retention of nanoparticles inside
the cells, inducing apoptosis. The preferential accumulation of
PTX-PLGA NPs within the cancer cells were also confirmed
by flow cytometry-based uptake studies. The results indicated
that Apt-PTX-PLGA NPs could be a promising targeted ther-
apeutic delivery vehicle for cancer treatment.
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1 Introduction
Targeted drug delivery is considered to be a very potential
and desired requirement in cancer chemotherapy. Most of
the anti-cancer drugs are non-specific and can also cause
injury to normal tissues (Sahoo and Labhasetwar 2003).
Nanotechnology has introduced new pathways for improved
therapeutic delivery using different types of nanoparticles to
eradicate tumor population without inducing toxicity to
normal tissues (Koo et al. 2005; Farokhzad and Langer
2009; Ferrari 2005; Praetorius and Mandal 2007). Diverse
biocompatible nanodrug carriers with controlled drug re-
lease have already been developed (Ravichandran 2009;
Bob 2004; Sahoo et al. 2007; Rawat et al. 2006). Success
of such carriers depend on their efficiency to encapsulate a
cytotoxic dose of chemotherapeutic drug and their capabil-
ity to functionalize a tumor specific ligand which can target
the tumor cells while sparing the surrounding normal tissues
(Suri et al. 2007; Wang et al. 2009; Davis 1997; Haley and
Frenkel 2008).
Nowadays, cancer drug delivery research is being focused
on developing innovative and effective tumor-targeted thera-
pies by utilizing various nanoparticles as drug carriers and
antibodies/peptides/aptamers as targeting moieties (Ray and
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White 2010; Toti et al. 2010; Arruebo 2009; Nobs et al. 2004).
Nanoparticles can accumulate within tumor cells by passive or
active process. Passive targeting implies that nanoparticles
smaller than the fenestrations of endothelial cells extravagate
at the leaky tumor vasculatures, penetrate, and get internalized
into the tumor interstitium. Active targeting involves drug
delivery to a specific site based on molecular recognition of
the receptor on the target cell by the targeting ligand coupled
to nanoparticles (Labhasetwar and D 2005; Domı et al. 2004;
Brannon-Peppas and Blanchette 2004).
Aptamers are a class of therapeutic oligonucleotides that
bind to cell surface receptors with high affinity and specificity
(Levy-Nissenbaum et al. 2008). This property of aptamers has
been exploited for developing targeted drug carriers which can
deliver variety of cargoes into cells. Aptamers possess several
unique properties whichmake them attractive tools for use in a
wide array of molecular biology applications and as potential
pharmaceutical agents (Cerchia and de Franciscis 2010; Ray
and White 2010). Aptamers bind to targets with high affinity
and are structurally stable across a wide range of temperature
and storage conditions. These can be chemically synthesized,
reducing the cost and intensive work of monoclonal antibody
production (Ireson and Kelland 2006; Mairal et al. 2008;
Mallikaratchy et al. 2009; Lee et al. 2006).
A 26-nucleotide guanosine-rich (G-rich) DNA sequence
(AS1411) discovered serendipitously by Bates et al. was found
to have anti-proliferative activity and subsequently found to
bind nucleolin (Bates et al. 2009). Nucleolin is a predominantly
nuclear and cytoplasmic phosphoprotein, which is also over-
expressed on the plasma membrane of some tumor cells com-
pared with that of normal cells. Nucleolin expression is corre-
lated with cell proliferation. Compared with normal cells, the
nucleolin levels are higher in tumor cells Soundararajan et al.
(n.d.). Moreover, cell surface nucleolin functions as a receptor
to various growth factors like midkine and pleiotrophin which
is required for the cells to grow efficiently, however if over
expressed can transform the cells. Therefore, the functional
blockage of the cell surface nucleolin represents a potential
target for the development of anti-cancer therapeutics. It was
proved that AS1411 inhibited the pro-survival NF–κB signal-
ing pathway and thus blocked DNA-replication and induced
cell cycle arrest and apoptosis. Furthermore, studies conducted
by Soundararajan et al. concluded that anti-nucleolin aptamer
inhibited the binding of nucleolin to bcl-2mRNA. This resulted
in the destabilization of the mRNAwith a consequent decrease
in the level of anti-apoptotic bcl-2 protein in the breast cancer
cells. Currently, the anti-nucleolin aptamer AS1411 is in phase
II clinical trials for acute myeloid leukemia and renal cell
carcinoma. Various in vitro and in vivo studies conducted so
far have demonstrated that the anti-nucleolin aptamer can target
nanoparticles to cancer cells expressing nucleolin on their cell
surface and can potentially be used as a non-invasive imaging
tool for the diagnosis of cancer (Soundararajan et al. 2009;
Ireson and Kelland 2006; Ozalp et al. 2011; Ray and White
2010; Jim and L 2011).
Paclitaxel (PTX) is a potent anti-cancer drug isolated from
the bark of Taxus brevifolia, which arrests the cell division
through stabilization of the microtubuli. PTX disrupts the dy-
namic equilibrium within the microtubule system and blocks
cells in the late G2 phase andM phase of the cell cycle, thereby
inhibiting cell replication (Mallikaratchy et al. 2009). PTX is a
very hydrophobic compound, and to enhance its solubility and
allow parenteral administration, commercial formulation of
paclitaxel (Taxol) is currently formulated at a concentration of
6 mg/ml in a vehicle containing non-ionic surfactant cremo-
phor (polyoxyethylated castor oil) and ethanol as solubilizing
agents at a ratio of 1:1. However, Cremophor® EL is correlated
with various hypersensitivity and toxicity issues like nephro-
toxicity and neurotoxicity; it can also alter endothelial function
causing vasodilatation, labored breathing, lethargy, and hypo-
tension (De et al. 2005; Jin et al. 2009; Gradishar et al. 2005).
Poly(lactide-co-glycolide) (PLGA) was chosen as a drug
carrier for paclitaxel due to its biodegradability and biocom-
patibility properties and its approval by the FDA. PLGA has
been extensively used in the formulation of particles for
various drug delivery applications (Esmaeili and Hossein
2008; Jin et al. 2009; Dong and Feng 2007; Feng et al.
2002). BS3 cross-linker (Thamake et al. 2011) was added to
allow functionalization of aptamer on to the surface of the
nanoparticle. In this study, we synthesized PTX-loaded
PLGA-based nanoparticles which showed an enhanced cy-
totoxic profile in vitro when compared with commercial
Taxol® (Xu et al. 2009; Vicari et al. 2008). We also found
that PTX-PLGA NPs conjugated with AS1411 aptamer
would target the tumor cells alone and would further en-
hance the anti-tumor efficacy of PTX as compared with non-
targeted PTX-PLGA nanoparticles (Dhar et al. 2008).
2 Materials and methods
The 50:50 PLGA(poly lactic-co-glycolic acid), MW 30–
70 kDa with an inherent viscosity of 0.59 dL/g, polyvinyl
alcohol (PVA), MW 12–23 kDa, 87–89% hydrolyzed, N-
hydroxysuccinimide (NHS), EDC (1-ethyl-3-(3-dimethyla-
minopropyl)-carbodiimide), and penicillin/streptomycin so-
lution were obtained from Sigma-Aldrich (St. Louis, MO).
Ethyl acetate and all other reagents used were supplied by
Fisher Scientific (Fairlawn, NJ). Paclitaxel was obtained
from Wako Chemicals. All reagents were of analytical
grade. Cell cultures chemicals-DAPI, trypan blue, trypsin
(0.25%), and MTT assay kit were purchased from Sigma-
Aldrich. Alamar blue stain was supplied by Invitrogen.
Aptamer AS1411 (NH2-5 ′-(GGTGGTGGTGGT
TGTGGTGGTGGTGG)-3′) and non-specific aptamer
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(NH2 -5′-(CCTCCTCCTCCTTCTCCTCCTCCTCC) - 3′)
were purchased from Operon.
2.1 Formulation of paclitaxel-loaded nanoparticles
Effective encapsulation of chemotherapeutic drug within the
nanoparticle depends on various factors like preparation meth-
od, polymer and drug composition, solvent and drug solubility,
and stabilizer composition (Fonseca et al. 2002). We have
adopted the nanoprecipitation-solvent evaporation method to
synthesis paclitaxel-loaded PLGA nanoparticles with minor
modifications. PVA, awidely known stabilizer for PLGAnano-
particles (Feng 2001), was employed in the synthesis along
with a hydrophobic eight-carbon spacer chain of homo-
bifunctional chemical cross-linker, bis(sulfosuccinimidyl) sub-
erate (BS3). This carbon spacer chain will align itself on the
nanoparticle surface with its COOH groups on the terminal
hydrophilic side extending towards the outside of the nano-
particle surface (Thamake et al. 2011). Paclitaxel, a highly
potent chemotherapeutic drug widely used against various
tumors, showed limited clinical success owing to its low ther-
apeutic efficiency and low solubility in many pharmaceutical
solvents (Jin et al. 2009). Upon incorporation within PLGA
nanoparticles, paclitaxel demonstrated enhanced therapeutic
index of the drug and lack of the toxic effects caused by its
commercial adjuvant Cremophor®EL (Gradishar et al. 2005).
Nanoparticles were prepared using a single-emulsion tech-
nique/solvent evaporation method that has been reported else-
where with slight modification (Thamake et al. 2011; Cartiera
et al. 2010). Briefly, 65 mg of PLGA dissolved in 1 ml of ethyl
acetate was added to 2.2% aqueous solution of PVA containing
0.5 mg ml−1 of BS3. This mixture was sonicated at room
temperature using an ultrasonic processor UP200H system
(Hielscher Ultrasonics GmbH, Germany) at 40% amplitude
for 2 min in continuous mode. The excess solvent was evapo-
rated by continuous stirring for 45 min to 1 h followed by
centrifugation at 10,500 rpm for 15 min to remove excess of
aqueous solution. The separated nanoparticles were washed by
resuspending in water three times. One milligram of paclitaxel
in 1 ml of ethyl acetate was added along with the polymer/
solvent mixture to prepare drug-loaded nanoparticles. Surface
morphology and size were also determined by high-resolution
scanning electron microscopy and atomic force microscopy.
2.2 Preparation of aptamer-conjugated drug-loaded
nanoparticles
In order to achieve an aptamer–nanoparticle bio-conjugate
capable of targeting desired cells, the binding protocol must
preserve the biological activity of the aptamer (Balamurugan et
al. 2008). Hence, special care was taken in choosing a suitable
covalent binding procedure for functionalizing the aptamer on
nanoparticle surface with effective binding by maintaining its
biological activity (Janas and Janas 2011). Amine-modified
AS1411 aptamer was conjugated on the carboxyl group carry-
ing nanoparticles using the common conjugation strategy of
carbodiimide chemistry (cross-linking of the carboxylic acid
group on the nanoparticle surface and the amine group of the
aptamer to form an amide linkage). The carboxyl groups on the
nanoparticle surface were converted to its succinimide by using
EDC and NHS, which was then allowed to react with NH2-
AS1411 aptamer. This method is well studied by many
researchers which effectively carried out the conjugation of
aptamer on to the polymer nanoparticles (Davies et al. 2010;
Ling et al. 2011; Farokhzad et al. 2004; Dhar et al. 2008).
PTX-PLGA NPs (10 μg/μL) was washed three times
with 250-μL aliquots of a 10 mM phosphate buffered saline
(PBS) (pH 7.4) and incubated with 200 μL of 400 mmol/L
EDC and 200 μL of100mmol/L NHS for 15 min at room
temperature with gentle shaking. The resulting NHS-activated
particles are covalently linked to amine-modified AS1411
aptamer (1 μg/μL). The sample was allowed to react for 2 h
with constant mixing at room temperature, and three final
washes were performed using the 20 mM Tris–HCl, 5 mM
MgCl2 at pH 8.0. The resulting aptamer–nanoparticle bio-
conjugates were resuspended and preserved in suspension
form in DNase–RNase-free water at 4°C before use.
2.3 Surface morphology characterization
The shape and surface morphology of paclitaxel-loaded PLGA
NPs were analyzed using a scanning electron microscope
(SEM) (FESEM, JSM-6700F, JEOL, Japan) at an accelerating
voltage of 3–5 kV. Nanoparticles were fixed to sample stubs
with double-sided carbon tape and sputter-coated with platinum
which was carried out by an Auto Fine Coater (JEOL, Tokyo,
Japan) for 50 s for viewing by SEM. For atomic force
Fig. 1 SEM image of PLGA-PTX nanoparticles
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microscopy (AFM), drug-loaded PLGA solution (200 μL) was
deposited on a glass surface and vacuum-dried. The sample
was characterized by AFM (Digital Instruments 3000AFM) in
tapping mode. Three-dimensional imaging of the drug-loaded
nanoparticles was done using transmission electronmicroscopy
(TEM, JEM 2200 FS, JEOL, Japan). One drop of the sample
solution was deposited onto a carbon-coated copper grid that
had been previously hydrophilized under UV light and air-dried
at room temperature prior to examination under TEM.
2.4 Surface chemistry characterization
The aptamer labeling on the surface of paclitaxel-loaded
PLGA NPs was confirmed from the surface chemistry mea-
sured by X-ray photoelectron spectroscopy (XPS, AXIS
His-165 Ultra, Kratos Analytical, Shimadzu Corporation,
Japan). Five microliters of the sample was applied on a
clean silicon substrate and dried in vacuum. The binding
energy spectrum was recorded from 0 to 1,000 eV with pass
energy of 80 eV under the fixed transmission mode.
2.5 Cell culture studies
GI-1 cells obtained from Riken Bio Resource Center, Japan,
were cultured in monolayers to 80% confluence by main-
taining in Dulbecco’s minimal essential medium (DMEM,
Gibco) supplemented with 10% fetal bovine serum and 1%
penicillin–streptomycin solution in a 5% CO2-humidified
atmosphere at 37°C. Normal human mammary epithelial
cells obtained from Gibco were maintained in HuMEC-
Fig. 2 AFM image of PLGA-PTX NPs
Fig. 3 XPS spectra of a
PTX-PLGA NPS, b Apt-PTX-
PLGA NPs, above N spectra of
c PTX-PLGA NPS and d
Apt-PTX-PLGA NPs
Fig. 4 2D-sliced image obtained from 3D-TEM imaging of PTX-
PLGA NPs
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ready medium (Gibco) supplemented with growth supple-
ments and antibiotics in 5% CO2-humidified atmosphere at
37°C. For use in experiments, 1×104cells/ml per well were
seeded in glass-based dish for confocal studies; approxi-
mately 5,000–8,000 cells were seeded in 96-well plates for
cytotoxic studies; 3×104 cells were plated in a 25-mL flask
for phase contrast studies, and 2.5×106 cells per well was
seeded in glass plate for flow cytometry studies.
2.6 Confocal microscopy
GI-1 cells were seeded in glass-based bottom well dish at a
density of 1×104 cells/ml. The plates were incubated at 37°
C and grown to 70% confluency. Cells were treated with a
fixed concentration, i.e., 100 μg/ml, of aptamer-conjugated
Nile red dye-tagged paclitaxel-loaded PLGA NPs (Apt-NR-
PTX-PLGA NPs) and aptamer-conjugated paclitaxel-loaded
PLGA nanoparticles (Apt-PTX-PLGA NPs) for different
time periods. The cells were incubated with the dye-loaded
particles and subjected to confocal microscopy after 2 and
120 h. The anticancer drug-loaded PLGA nanoparticles
were incubated with the cells and subjected to confocal
microscopy at 24, 72, and 120 h.
At the end of the incubation period, the cell monolayers
were rinsed three times with 1 ml of PBS buffer (0.01 M,
7.4) to remove excess nanoparticles or free dye. Apt-NR-
PLGA NPs-treated cells were stained with lysotracker (Sig-
ma) to mark the location of endosomes within the cells.
Nanoparticles gain entry into the cells by means of
endosome-mediated transport. The Apt-PTX-PLGA NPs
treated cells were stained with tubulin marker to selectively
mark the micro-spindles. This is to evaluate the action of
Fig. 5 Confocal images of (a)
HMEC cells (b) GI-1 cells
treated with Apt-PTX-PLGA
NPs after 24 hours (c) HMEC
cells (d) GI-1 cells treated with
Apt-PTX-PLGA NPs after
72 hours (e) HMEC (f) GI-1
cells treated with Apt-PTX-
PLGA NPs after 120 hours
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paclitaxel released from the PLGA nanoparticles. Fresh PBS
(0.01 M, pH 7.4) buffer was added to the plates, and the
cells were viewed and imaged under a confocal laser scan-
ning microscope (Leica TCS SP5, Leica Microsystems
GmbH, Germany) equipped with an argon laser using FITC
filter (Ex 488 nm, Em525 nm) and Red filter (Ex 561 nm).
The images were processed using Leica Application Suite
software.
2.7 In vitro cell viability assay
Bioassay of cell viability was investigated by means of the
cellular mitochondrial activity (using methylthiazolyldiphenyl-
tetrazolium bromide or MTT assay). GI-1 cell line and normal
HMEC cells were exposed to plain paclitaxel(Taxol), plain
PLGA nanoparticles(Plain-PLGA NPs), paclitaxel-loaded
PLGA nanoparticles(PTX-PLGA), specific aptamer-labeled
paclitaxel-loaded PLGA nanoparticles (AS1411-PTX-PLGA
NPs), and non-specific aptamer-labeled paclitaxel-loaded
PLGA nanoparticles (NS-PTX-PLGA NPs) at a concentration
of 100 μg/ml for a 24-h duration. The NPs were sterilized with
UV irradiation for 30 min before use. At given time interval,
the cultured cells were assayed for cell viability with MTT
(Sigma). The wells were washed twice with PBS, and 10 μl of
MTT (5 mg/mL, Sigma) supplemented with culture medium
was added. After 4 h incubation in the incubator, the culture
medium was removed, and the precipitate (formazan crystals)
was dissolved in 100 μL of dimethylsulfoxide. Relative per-
centage of metabolically active cells relative to untreated con-
trols was then determined on the basis of the mitochondrial
conversion of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide to formazan by cellular mito-
chondrial dehydrogenase present in viable cells. The amount
of 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide that is converted to formazan indicates the number of
viable cells. The results were assessed in a 96-well format
Fig. 6 Confocal images of
GI-1 Cells treated with
Apt-PTX-PLGA NPs after
24 hours (a) NR-tagged
Apt-PTX-PLGA particles (b)
Lysotracker stained lysosomes.
Images of GI-1 Cells treated
with Apt-PTX-PLGA NPs after
120 hours (c) NR-tagged
Apt-PTX PLGA particles and
(d) Lysotracker stained
lysosomes
Fig. 7 Alamar blue assay analysis of PTX-PLGA NPs and Apt-PTX-
PLGA at time intervals 24, 48, 72 h
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micro plate reader by measuring the absorbance at a wave-
length of 490 nm.
Another 96-well plate of GI-1 cells (5,000 cells/100 μl per
well) was plated to make a comparison of the anti-proliferative
effect of PTX-PLGA NPs and Apt-PTX-PLGA NPs on the
cancer cells. Assays based on the cellular metabolic activity
(using Alamar blue or AB), was performed after treating the
cells with varying concentrations (0.001 μg–1 μg/ml) of the
PTX-PLGA NPs and Apt-PTX-PLGA NPs for 24, 48, and
72 h. Alamar blue assay evaluates the proliferation and met-
abolic activity of cells. In living cells, the mitochondrial
reductase enzymes are active and reduce Alamar blue to form
a different-colored product from the blue dye. This reducing
ability of the cells explains the active metabolism taking place
within the cells. When the samples added to the cells are toxic
in nature, the reducing ability of the cells to reduce the dye
decreases. By measuring the fluorescence intensity of Alamar
blue dye at 590–620 nm, the cell viability was determined.
This colorimetric cell proliferation assays allow for easy and
reliable colorimetric determination of viable cell numbers with
excellent sensitivity. All the experiments were repeated in
triplicate. Just before adding MTT reagent, representative
phase contrast microscope images of cells were taken using
an Olympus BX 41 microscope (Olympus, Center Valley, PA,
USA).
2.8 Flow cytometry
GI-1 cells and HMEC cells were plated at a density of 2.5×
106 cells per well in DMEM medium and HuMEC-Ready
medium, respectively, and incubated at 37°C until it attained
70% confluence. The culture medium was replaced with Apt-
NR-PLGA NPs suspension medium for 1–3 h at 37°C. The
incubated cells were washed three times with cold PBS and
trypsinized. The pellet was washed with PBS three times and
fixed with 1% (w/v) para-formaldehyde solution. DAPI stain-
ing was done to stain the nucleus. The cellular uptake of
nanoparticles by the cells was investigated by flow cytometry
(FACScan, Becton Dickinson).
3 Results and discussion
3.1 PLGA drug delivery carriers suitable for aptamer
functionalization
The surface morphology of the paclitaxel-loaded PLGA
nanoparticles was analyzed by SEM and AFM. Under
SEM observation, we found that the morphology of
paclitaxel-loaded PLGA nanospheres fabricated with PVA
had fine spherical shape with a smooth surface (Fig. 1)
while the size of the particles ranged from 100 nm to
1 μm; most of the nanosphere sizes were skewed to about
200 nm. For cell culture work, we optimized the size of the
particles to below 200 nm by filtering the particle solution
through 0.2 μm Millipore syringe filter. Fig. 2 shows the
AFM image of the filtered nanoparticles taken under high
resolution. It was observed that the particles were of smooth
surface and had a uniform size distribution of 200 nm.
3.2 Aptamer conjugation and surface chemistry analysis
Surface chemistry of the nanoparticles prepared by the sol-
vent extraction/evaporation technique was analyzed by
Fig. 8 MTT cytotoxicity assay results of Plain PTX, plain PLGA NPs, PTX-PLGA NPs, AS1411-PTX-PLGA NPs and non-specific Apt-PTX-
PLGA NPs
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XPS. Paclitaxel is the only substance which contains nitro-
gen in the nanoparticles prepared with PVA as emulsifier
(Feng 2001). Therefore, nitrogen can be the characteristic
element of paclitaxel. While scanning PTX-PLGA NPs, the
scan of nitrogen failed to detect the existence of N1s core-
level signal on the exterior. This fact may be attributed to the
very low solubility of paclitaxel in water, which makes the
drug tend to stay inside polymeric nanoparticle rather than
diffuse from one to another (Feng et al. 2002).
Fig. 3 explains the N 1 s XPS spectra of the surface of the
PTX-PLGA NPs with and without aptamer conjugation.
Paclitaxel contains nitrogen element, but there is no N 1 s
signal detected from the surface of the PTX-PLGA NPs,
which proved that the drug was completely encapsulated
inside the polymeric matrix of the NPs. The successful
aptamer conjugation on the NP surface can be confirmed
by the presence of the N 1 s region in the XPS spectra of
Apt-PTX-PLGA NPs. XPS analysis supported the conclu-
sion of successful conjugation of the aptamer on the poly-
meric nanoparticles by showing the nitrogen peak, which
was completely absent in the PTX-PLGA NPs without
aptamer treatment.
The encapsulation of drug within the PLGA NPs was
further confirmed by means of 3D TEM imaging. From
Fig. 4, we can clearly distinguish the inner core and outer
surface of the drug-loaded nanoparticles leading to the con-
firmation of successful drug encapsulation within the nano-
particles. Further in vitro cytotoxic cell studies conducted
for the drug-loaded PLGA nanoparticles supports the drug
being entrapped within the particles.
Fig. 9 Phase contrast images of
(a) Control GI-1 cells (b) GI-1
cells treated with Plain PLGA
NPs (c) GI-1 cells treated with
Plain PTX (d) GI-1 cells treated
with PTX-PLGA NPs (e) GI-1
cells treated with Apt AS1411-
PTX-PLGA NPs (f) GI-1 cells
treated with non-specific
aptamer-PTX-PLGA NPs
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3.3 In vitro cellular uptake: confocal microscopy studies
Confocal microscopy of normal HMEC cells and GI-1 tumor
cells exposed to Apt-PTX-PLGA NPs demonstrated in-
creased cytotoxic effect on tumor cells alone with the in-
crease in the time of incubation. The cells were subjected to
confocal microscopy after treating with the particles for 24,
72, and 120 h. At each interval, the cells were washed with
PBS, stained with tubulin marker to mark the micro-spindles.
Paclitaxel, a microtubule-targeted anti-cancer drug exerts its
anticancer effects by causing abnormal stabilization of the
dynamic microtubule polymerization leading to the failure of
mitotic cell cycle and induction of apoptotic cell death
(Alexandre et al. 2007). The normal HMEC cells grew
normally in general culture conditions and were not affected
by the presence of drug-loaded nanoparticles. In tumor GI-1
cells, by utilizing the tumor vasculature and receptor-
mediated endocytosis, Apt-PTX-PLGA NPs was capable of
entering the cells and exerting anti-proliferative effect and
induced apoptosis (Fig. 5a–f).
Fig. 11 Flow cytometry analysis of cells treated with particles a DAPI filter, b Red filter
Fig. 10 Flow cytometry analysis
—control cells (purple); normal
cells treated with Apt-NR-PLGA
NPs (blue) and tumor cells treated
with Apt-NR-PLGA NPs (green)
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Figure 6a–b represents the confocal images of cells treated
with Apt-NR-PTX-PLGA NPs to study the localization of the
particles within the cells. The cells were treated with these
particles for 2 and 120 h. At each interval, the cells were
washed with PBS and stained with lysotracker. In Fig. 6a, after
2 h incubation of the particles with the cells, we can identify the
Apt-NR-PTX-PLGA NPs in the endosomes present in the
cytoplasm of the cells. In the case of 120 h incubation of the
particles with the cells, due to the action of paclitaxel, the cells
undergo apoptosis, and the image clearly shows the scattered
cytoplasm and the nanoparticles released from the cells
(Fig. 6b).
3.4 In vitro cytotoxicity
The potential of PTX-PLGA formulations to kill the cancer
cells is reflected by their cytotoxicity against the cancer cells.
MTT assays were performed using equivalent concentrations
of commercial paclitaxel, plain PLGA nanoparticles,
paclitaxel-loaded PLGA nanoparticles with and without
aptamer conjugation, and non-specific aptamer-conjugated
paclitaxel-loaded PLGA nanoparticles. A comparative study
of cytotoxicity was done using Alamar blue assay for plain
PTX-PLGA nanoparticles and AS1411 aptamer-conjugated
PTX-PLGA NPs (Fig. 7). Untreated cells served as controls;
the assay was terminated at 72 h, and cell viability was
determined via colorimetric determination.
Figure 8 shows the in vitro viability of GI-1 cells and
HMEC cells after 24 h treatment of paclitaxel, plain PLGA
nanoparticles, PTX-PLGA NPs, Apt-PTX-PLGA NPs, and
also with non-specific aptamer-conjugated PTX-PLGA
nanoparticles at a concentration of 100 μg/mL. From the
cytotoxic assays and phase contrast microscopy images of
cells treated with particles (Fig. 9a–f), we can infer that (1)
the plain PLGA NPs are biocompatible and non-toxic
(Fig. 9b); (2) the NP drug formulation demonstrated more
efficiency in arresting cell growth than the commercial drug
(Fig. 9c–d); and (3) the cellular viability decreased with the
incubation period in all cases (Fig. 8).
Moreover, Fig. 7 clearly demonstrates the specific targeting
effect of the aptamer conjugation on the PTX-PLGA nano-
particles. It can be seen from Fig. 7 in case of GI-1 cells (1) the
cellular viability decreased from 63.16% for PTX-PLGA NP
formulation (no aptamer conjugated) to 30.75% for the Apt-
PTX-PLGA NP formulation for 24 h incubation; (2) the
cellular viability decreased from 49.67% for PTX-PLGA NP
formulation to 21.07% for the Apt-PTX-PLGA NP formula-
tion for 48 h incubation; and (3) the cellular viability de-
creased from 18.36% for PTX-PLGA NP formulation to
15% for the Apt-PTX-PLGANP formulation for 72 h, respec-
tively. We can thus conclude that the targeting effect of the
Apt-PTX-PLGA nanoparticles is highly significant in the
targeted drug delivery.
3.5 In vitro cellular uptake: flow cytometry
The relative extent of cellular uptake was qualitatively ana-
lyzed by a flow cytometry method. The flow cytometry
measures the fluorescence intensity of each cell and plots
it against the number of cells. From flow cytometry results
as shown in Fig. 10, fluorescence intensity of GI-1 cells
incubated with Apt-NR-PTX-PLGA nanoparticles was
stronger than that of HMEC cells with Apt-NR-PTX-PLGA
NPs or control, indicating that the Apt-NR-PTX-PLGA NPs
were specifically recognized by GI-1 tumor cells. In the case
of the GI-cells incubated with Apt-NR-PTX-PLGA NPs,
there was a shift in the red fluorescence intensity to the right
direction, indicating that the cellular uptake of NR-PTX-
PLGA nanoparticles was significantly enhanced due to
aptamer-mediated endocytic delivery of nanoparticles into
the cells. In addition, the overlapping of both DAPI channel
and Red filter channel signals indicates the presence of
nanoparticles within the same cell (Fig. 11).
4 Conclusions
In this study, the feasibility of targeting nanoparticles to spe-
cific tumor cells and cell internalization was demonstrated.
Nanoparticles of PLGA polymer loaded with paclitaxel as a
model anticancer drug were prepared by the solvent extrac-
tion/evaporation single-emulsion method and then functional-
ized with AS1411 aptamer specific for nucleolin protein for
controlled and targeted chemotherapy. The targeting effect
was qualitatively and quantitatively investigated by cancer
cell uptake of the Nile red-tagged Apt-PTX-PLGA NPs and
further confirmed by the cytotoxicity of the cancer cells trea-
ted with the Apt-PTX-PLGA NPs for various time intervals.
We conclude that the PTX-PLGA nanoparticle formulation
has great advantages over the commercial Taxol, and the
aptamer conjugation can significantly promote targeted deliv-
ery of the drug to the corresponding cancer cells and thus
enhance its therapeutic effects and reduced its side effects.
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